Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) EBIT Margin (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBIT Margin for 2 consecutive years, with 700.35% as the latest value for Q2 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 700.35% in Q2 2025 year-over-year; TTM through Sep 2025 was 3765.74%, a N/A change, with the full-year FY2024 number at 554.07%, changed N/A from a year prior.
  • EBIT Margin was 700.35% for Q2 2025 at Pyxis Oncology, down from 34.71% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 34.71% in Q1 2024 to a low of 700.35% in Q2 2025.